Page 400 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 400
PhoenixBio 400 G
1-3-4, Kagamiyama
7390046, Higashi-Hiroshim
Japan
www.phoenixbio.co.jp/en/
PhoenixBio Co., Ltd. is a Japanese company producing the PXB-Mouse® chimeric animal
model, a unique in-vivo research tool for drug discovery and development with a liver up to
95% replaced by human hepatocytes.We apply this tool in the fields of virology and ADME/
Toxicology by providing high quality in-house in-vivo drug efficacy evaluations of both anti
HBV and HCV entry and replication inhibitors together with ADME and Toxicology study
services for the prediction of human responses to match the growing need for more accurate
and relevant preclinical data in the field of drug discovery and development.
PRO.MED.CS Praha a.s. 450 A
1, Telčská
14000, Prague
Czech Republic
www.promedcs.eu
PRO.MED.CS Praha a.s. is a leading independent Czech manufacturer of medicinal
products for human use with its own research and development facilities. PRO.MED.CS
specialises in producing tablets, coated tablets and capsules, manufacturing over 1.5 million
units daily. The portfolio primarily focuses on gastrointestinal and cardiovascular medicine.
PRO.MED.CS exports to 30 countries around the world, especially the Russian Federation,
Central and Eastern Europe and Central Asia. In recent years it has also been gaining a
foothold on West European markets. The company’s main goal is to bring proven, effective,
safe and affordable products to market.
INDUSTRY INFORMATION RESONANCE HEALTH ANALYSIS SERVICES LTD 440 I
278 Stirling Highway
6010, Claremont
Australia
www.resonancehealth.com
Resonance Health specialises in quantitative MR image analysis. FerriScan® provides an
accurate measurement of liver iron concentration, critical in the management of patients
with potentially fatal iron overload conditions. HepaFat-Scan™ provides a quantitative
measurement of liver fat. The technology has been clinically validated against independent
measurements of the volume fraction of fat in liver biopsy specimens in a clinical study.
Both FerriScan® and HepaFat-Scan™ are regulatory cleared (FDA, CE Mark, TGA) and
easy to implement on widely available 1.5T MRI platforms. Resonance Health also provides
imaging core lab services to pharmaceutical companies undertaking clinical trials for drugs
under development.
400 The International Liver Congress™ 2015 • ILC Programme
1-3-4, Kagamiyama
7390046, Higashi-Hiroshim
Japan
www.phoenixbio.co.jp/en/
PhoenixBio Co., Ltd. is a Japanese company producing the PXB-Mouse® chimeric animal
model, a unique in-vivo research tool for drug discovery and development with a liver up to
95% replaced by human hepatocytes.We apply this tool in the fields of virology and ADME/
Toxicology by providing high quality in-house in-vivo drug efficacy evaluations of both anti
HBV and HCV entry and replication inhibitors together with ADME and Toxicology study
services for the prediction of human responses to match the growing need for more accurate
and relevant preclinical data in the field of drug discovery and development.
PRO.MED.CS Praha a.s. 450 A
1, Telčská
14000, Prague
Czech Republic
www.promedcs.eu
PRO.MED.CS Praha a.s. is a leading independent Czech manufacturer of medicinal
products for human use with its own research and development facilities. PRO.MED.CS
specialises in producing tablets, coated tablets and capsules, manufacturing over 1.5 million
units daily. The portfolio primarily focuses on gastrointestinal and cardiovascular medicine.
PRO.MED.CS exports to 30 countries around the world, especially the Russian Federation,
Central and Eastern Europe and Central Asia. In recent years it has also been gaining a
foothold on West European markets. The company’s main goal is to bring proven, effective,
safe and affordable products to market.
INDUSTRY INFORMATION RESONANCE HEALTH ANALYSIS SERVICES LTD 440 I
278 Stirling Highway
6010, Claremont
Australia
www.resonancehealth.com
Resonance Health specialises in quantitative MR image analysis. FerriScan® provides an
accurate measurement of liver iron concentration, critical in the management of patients
with potentially fatal iron overload conditions. HepaFat-Scan™ provides a quantitative
measurement of liver fat. The technology has been clinically validated against independent
measurements of the volume fraction of fat in liver biopsy specimens in a clinical study.
Both FerriScan® and HepaFat-Scan™ are regulatory cleared (FDA, CE Mark, TGA) and
easy to implement on widely available 1.5T MRI platforms. Resonance Health also provides
imaging core lab services to pharmaceutical companies undertaking clinical trials for drugs
under development.
400 The International Liver Congress™ 2015 • ILC Programme
